Update shared on10 Aug 2025
Fair value Increased 9.71%Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation.
What's in the News
- Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.
- The company was added as a constituent to a range of Russell growth indexes, including Russell 1000, 2500, 3000, Midcap, and Small Cap Comp Growth Benchmarks and Indexes, enhancing its visibility among growth investors.
Valuation Changes
Summary of Valuation Changes for Sotera Health
- The Consensus Analyst Price Target has risen from $14.58 to $15.75.
- The Net Profit Margin for Sotera Health has significantly risen from 18.65% to 23.20%.
- The Future P/E for Sotera Health has significantly fallen from 21.74x to 18.17x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.